Total Payments
$98,304
2024 Payments
$2,100
Companies
10
Transactions
70
Payment Breakdown by Category
Consulting$55,270 (56.2%)
Travel$31,979 (32.5%)
Research$8,475 (8.6%)
Food & Beverage$1,380 (1.4%)
Other$1,200 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $55,270 | 15 | 56.2% |
| Travel and Lodging | $31,979 | 17 | 32.5% |
| Unspecified | $8,475 | 12 | 8.6% |
| Food and Beverage | $1,380 | 25 | 1.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,200 | 1 | 1.2% |
Payments by Type
General
$89,829
58 transactions
Research
$8,475
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk AS | $34,939 | 10 | $0 (2018) |
| Bayer HealthCare Pharmaceuticals Inc. | $20,493 | 13 | $0 (2017) |
| Shire North American Group Inc | $19,158 | 16 | $0 (2019) |
| SANOFI US SERVICES INC. | $9,825 | 13 | $0 (2024) |
| BioMarin Pharmaceutical Inc. | $6,810 | 8 | $0 (2023) |
| BIOVERATIV THERAPEUTICS INC. | $4,520 | 4 | $0 (2019) |
| Grifols Shared Services North America, Inc. | $2,474 | 3 | $0 (2017) |
| CSL Behring | $45.87 | 1 | $0 (2017) |
| GENZYME CORPORATION | $20.35 | 1 | $0 (2019) |
| Kedrion Biopharma Inc. | $18.80 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,100 | 2 | SANOFI US SERVICES INC. ($2,100) |
| 2023 | $2,850 | 3 | SANOFI US SERVICES INC. ($1,650) |
| 2022 | $3,225 | 4 | SANOFI US SERVICES INC. ($3,225) |
| 2021 | $2,850 | 5 | SANOFI US SERVICES INC. ($2,850) |
| 2019 | $14,950 | 19 | Shire North American Group Inc ($10,410) |
| 2018 | $33,542 | 14 | Novo Nordisk AS ($19,184) |
| 2017 | $38,787 | 23 | Bayer HealthCare Pharmaceuticals Inc. ($20,493) |
All Payment Transactions
70 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/02/2024 | SANOFI US SERVICES INC. | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 05/15/2024 | SANOFI US SERVICES INC. | — | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| 12/11/2023 | BioMarin Pharmaceutical Inc. | Roctavian (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: Hemophilia A | ||||||
| 11/22/2023 | SANOFI US SERVICES INC. | — | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| 02/01/2023 | SANOFI US SERVICES INC. | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 05/04/2022 | SANOFI US SERVICES INC. | — | — | Cash or cash equivalent | $750.00 | Research |
| Study: ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inhibitory Antibodies to Factor VIII or IX | ||||||
| 04/27/2022 | SANOFI US SERVICES INC. | — | — | Cash or cash equivalent | $975.00 | Research |
| Study: ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inhibitory Antibodies to Factor VIII or IX | ||||||
| 04/27/2022 | SANOFI US SERVICES INC. | — | — | Cash or cash equivalent | $900.00 | Research |
| Study: ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inhibitory Antibodies to Factor VIII or IX | ||||||
| 04/27/2022 | SANOFI US SERVICES INC. | — | — | Cash or cash equivalent | $600.00 | Research |
| Study: ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inhibitory Antibodies to Factor VIII or IX | ||||||
| 04/21/2021 | SANOFI US SERVICES INC. | — | — | Cash or cash equivalent | $600.00 | Research |
| Study: ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, with Inhibitory Antibodies to Factor VIII or IX | ||||||
| 04/21/2021 | SANOFI US SERVICES INC. | — | — | Cash or cash equivalent | $600.00 | Research |
| Study: ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, with Inhibitory Antibodies to Factor VIII or IX | ||||||
| 04/21/2021 | SANOFI US SERVICES INC. | — | — | Cash or cash equivalent | $600.00 | Research |
| Study: ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inhibitory Antibodies to Factor VIII or IX | ||||||
| 04/21/2021 | SANOFI US SERVICES INC. | — | — | Cash or cash equivalent | $600.00 | Research |
| Study: ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, with Inhibitory Antibodies to Factor VIII or IX | ||||||
| 04/21/2021 | SANOFI US SERVICES INC. | — | — | Cash or cash equivalent | $450.00 | Research |
| Study: ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, with Inhibitory Antibodies to Factor VIII or IX | ||||||
| 11/01/2019 | BIOVERATIV THERAPEUTICS INC. | FITUSIRAN (Drug) | — | Cash or cash equivalent | $900.00 | Research |
| Study: Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX | ||||||
| 11/01/2019 | BIOVERATIV THERAPEUTICS INC. | FITUSIRAN (Drug) | — | Cash or cash equivalent | $900.00 | Research |
| Study: Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX | ||||||
| 11/01/2019 | BIOVERATIV THERAPEUTICS INC. | FITUSIRAN (Drug) | — | Cash or cash equivalent | $600.00 | Research |
| Study: Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX | ||||||
| 07/07/2019 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Food and Beverage | In-kind items and services | $20.35 | General |
| 03/28/2019 | Shire North American Group Inc | — | Consulting Fee | Cash or cash equivalent | $8,550.00 | General |
| 03/21/2019 | BIOVERATIV THERAPEUTICS INC. | BIVV001 (Drug) | Consulting Fee | Cash or cash equivalent | $2,120.00 | General |
| 02/22/2019 | Shire North American Group Inc | — | Travel and Lodging | In-kind items and services | $571.51 | General |
| 02/22/2019 | Shire North American Group Inc | — | Travel and Lodging | In-kind items and services | $458.74 | General |
| 02/22/2019 | Shire North American Group Inc | — | Travel and Lodging | In-kind items and services | $205.42 | General |
| 02/22/2019 | Shire North American Group Inc | — | Food and Beverage | In-kind items and services | $157.11 | General |
| 02/22/2019 | Shire North American Group Inc | — | Food and Beverage | In-kind items and services | $132.27 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inhibitory Antibodies to Factor VIII or IX | SANOFI US SERVICES INC. | $3,825 | 5 |
| Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX | BIOVERATIV THERAPEUTICS INC. | $2,400 | 3 |
| ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, with Inhibitory Antibodies to Factor VIII or IX | SANOFI US SERVICES INC. | $2,250 | 4 |
About Gilbert White, MD, MS
Gilbert White, MD, MS is a Hematology & Oncology healthcare provider based in Milwaukee, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1073686010.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Gilbert White, MD, MS has received a total of $98,304 in payments from pharmaceutical and medical device companies, with $2,100 received in 2024. These payments were reported across 70 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($55,270).
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Milwaukee, WI
- Active Since 11/16/2006
- Last Updated 10/18/2012
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1073686010
Products in Payments
- ADYNOVATE (Biological) $8,748
- BMN 270 (Biological) $5,610
- Alphanate (Biological) $2,474
- FITUSIRAN (Drug) $2,400
- BIVV001 (Drug) $2,120
- Roctavian (Drug) $1,200
- Afstyla (Biological) $45.87
- NO PRODUCT DISCUSSED (Drug) $20.35
- RHOGAM (Drug) $18.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Milwaukee
Dr. Parameswaran Hari, Md, MD
Hematology & Oncology — Payments: $1.9M
Hematology & Oncology $1.9M
Dr. Lynn Malec, Md, MD
Hematology & Oncology — Payments: $597,741
Hematology & Oncology $597,741
Dr. Ehab Atallah, Md, MD
Hematology & Oncology — Payments: $481,534
Hematology & Oncology $481,534
Dr. Sayed Mehdi Hamadani, M.d, M.D
Hematology & Oncology — Payments: $452,049
Hematology & Oncology $452,049
Dr. Deepak Kilari, M.d, M.D
Hematology & Oncology — Payments: $351,939
Hematology & Oncology $351,939
Razelle Kurzrock, M.d, M.D
Hematology & Oncology — Payments: $252,132
Hematology & Oncology $252,132